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Introduction
Endothelin-1 (ET-1), a 21-amino-acid peptide, is a potent vasoconstrictor and pressor substance mainly produced by vascular endothelial cells (1) . ET-1 is thought to contribute to the development of cardiovascular diseases, and is assumed to modulate vascular tone and blood flow and promote vascular cell growth in an autocrine or paracrine fashion through two subtypes of receptor (2) . In a previous clinical study, the plasma ET-1 level was significantly higher in essential hypertensive patients (3) . Furthermore, an elevated ET-1 level has been associated with carotid atherosclerosis and asymptomatic cerebrovascular lesions in patients with logically inactive (8) .
There are two single nucleotide polymorphisms in the ET-1 gene (EDN1) that are associated with blood pressure (BP). A G-to-T transversion in exon 5 that causes the Lys-to-Asn substitution at codon 198 has been reported (9) (10) (11) . Recent association studies suggest that the Lys198Asn polymorphism interacts with BP in overweight people (9, 10) , or with body mass index (BMI) in association with hypertension (11) . Concerning plasma ET-1 level, pregnant women with the Asn/ Asn genotype have significantly elevated plasma ET-1 levels, and the Asn-allele has been associated with raised systolic BP (SBP), suggesting the functional importance of this polymorphism in pregnancy (12) . In a study using human mammary artery rings in vitro, artery segments from individuals with the Lys/Lys genotype were found to have an elevated response to phenylephrine-induced contractions compared to those with the Lys/Asn or Asn/Asn genotype (13) .
Another polymorphism associated with hypertension is the 3A/4A variant ( 134delA) located 138 bp downstream from the transcription start site in the 5 -untranslated region in EDN1 (14, 15) . In an in vitro assay for using the luciferase reporter gene, Popowski et al. reported that the 4A allele showed increased expression compared to the 3A allele (16) . Furthermore, the human umbilical vein endothelial cells (HUVECs) obtained from homozygotes with the 4A allele showed a significantly increased expression of ET-1 protein due to enhanced mRNA stability (16) . However, the association of plasma ET-1 levels with the 3A/4A genotypes has not been investigated.
The studies on the Lys198Asn polymorphism so far performed (9-13) have raised the question of whether the Lys198Asn polymorphism by itself has functional significance or, alternatively, whether it is linked to another variant in the EDN1 gene. The Lys198Asn polymorphism is located near the carboxyl terminal region, which is removed from preproET-1 by the proteolytic action of the furin-like enzyme (Fig. 1) . If the EDN1 Lys198Asn polymorphism is directly involved in the ET-1 function, it may affect the processing of preproET-1 to mature ET-1 through big ET-1 formation. To test this hypothesis, we performed transfection experiments. We measured the concentration of ET-1 and big ET-1 in the culture supernatant obtained from Lys-type or Asn-type transfectants using three different cell lines. In addition, we measured the plasma levels of ET-1 and investigated the influence of two EDN1 polymorphisms, Lys198Asn and 3A/4A, on the plasma ET-1 level in patients with hypertension.
Methods

Cell Culture
COS1 cells and 293 cells were purchased from American Type Culture Collection (Manassas, USA), and HUVECs were purchased from CellSystems (St. Katharinen, Germany). COS1 and 293 cells were cultured in DMEM medium (Invitrogen, Carlsbad, USA) supplemented with 10% fetal bovine serum (FBS) (JRH Biosciences, Lenexa, USA), while HUVECs were cultured on a type I collagen-coated culture dish in MCDB131 medium (Invitrogen) supplemented with 10 mmol/l GlutaMAX (Invitrogen), 20 mmol/l HEPES (Invitrogen), 2% FBS, and 10 ng/ml basic fibroblast growth factor (Roche Diagnostics, Mannheim, Germany). These cells were incubated in humidified 5% CO2 in air at 37 ºC. HUVECs were used for the experiments after 3-5 passages.
Site-Directed Mutagenesis
The preproendothelin-1 cDNA covering the entire coding region was subcloned between the EcoRI and SalI sites of the pCI mammalian expression vector (Promega, Madison, USA). Since this cDNA encodes Lys at codon 198, the obtained expression vector was designated pCI/hET-1/Lys. To replace Lys with Asn at codon 198, site-directed mutagenesis was performed. The following primers were used for polymerase chain reaction with a Pfu DNA polymerase (Stratagene, La Jolla, USA) (the mutated codon is underlined): forward 5 -CAAGCTGAAAGGCAATCCCTCCAGAGAGCG-3 , and reverse 5 -CGCTCTCTGGAGGGATTGCCTTTCAGCTTG -3 . Successful introduction of this mutation was confirmed by sequencing the entire coding region, and the obtained plasmid was designated pCI/hET-1/Asn.
Transient Expression and Measurement of the Concentration of Extracellular ET-1
COS1 cells were seeded at 1 10 5 cells/well in six-well plates on the day before transfection, and transfected with a mixture of 1 µg of expression plasmid (pCI/hET-1/Lys, pCI/hET-1/Asn or pCI) and 5 ng of pMI-SEAP (Roche Diagnostics) using 5 µl of Polyfect Transfection Reagent (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. After a 24-h incubation, the culture medium was exchanged to fresh medium containing 10% FBS. The transfected cells were incubated for another 24 h and then the culture supernatant was collected for measurement of immunoreactive ET-1 and big ET-1. The activity of secreted human placental alkaline phosphatase (SEAP) in the culture supernatant was measured by SEAP Reporter Gene Assay (Roche Diagnostics) for normalization of the transfection efficiency. The 293 cells were seeded at 2 10 5 cells/well in six-well plates and transfected by the same method as used for the COS1 cells, except for the use of 3 µl of FuGENE 6 Transfection Reagent (Roche Diagnostics). HUVECs were seeded at 1 10 5 cells/well in six-well plates and transfected with a mixture of 0.5 µg of expression plasmid and 5 ng of pMI-SEAP using 3 µl of FuGENE 6 Transfection Reagent. After a 6-h incubation, the culture medium was exchanged with fresh medium. The transfected cells were incubated for another 42 h, and then the culture supernatant was collected. The amounts of immunoreactive ET-1 and big ET-1 in the culture supernatant were measured by enzyme-linked immunosorbent assay (ELISA) using the Endothelin-1 Measurement Kit-IBL and Human Big Endothelin-1 Measurement Kit-IBL, respectively (Immuno-Biological Laboratories Co., Ltd., Fujioka, Japan).
Comparison of the Plasma ET-1 Level between Each Genotype in EDN1 Gene Polymorphisms
We measured the plasma ET-1 level and genotyped two EDN1 gene polymorphisms, Lys198Asn (5727G>T) in exon 5 and 3A/4A in the 5 -untranslated region ( 134delA), in 54 randomly selected essential hypertensive patients enrolled at the Division of Hypertension and Nephrology at the National Cardiovascular Center. All subjects provided written informed consent to participate in the study, and the study protocol was approved by the Ethical Review Committee of the National Cardiovascular Center. The plasma ET-1 level was measured by radioimmunoassay after extraction (17) . Genotyping was performed by the TaqMan PCR method using the following probes and primers: for Lys198Asn, probes Fam-AGGCAAGCCCTCCA-MGB (Lys-allele), Vic-AAGG CAATCCCTCCAG-MGB (Asn-allele), and primers 5 -CAG CGTCAAATCATCTTTTCATG-3 and 5 -GTCACCAATG TGCTCGGTTGT-3 , and for 3A/4A, probes Fam-AGTGCC CTTTTAACGG-MGB (4A-allele) and Vic-AAGTGCCC TTTAACGG-MGB (3A-allele), and primers 5 -AAACAGC TTCAGGTCCCTCAAA-3 and 5 -GCAGTCCCAGCTCTC CACC-3 (18) .
Statistical Analysis
The comparison of ET-1 and big ET-1 levels in the culture supernatant between the different transfected cell lines, and of the plasma ET-1 level and all of the clinical parameters between the two genotypes in patients with essential hypertension were performed by unpaired Student's t-test using the program StatView (SAS Institute, Inc., Cary, USA). A value of p<0.05 was considered to be statistically significant. In order to evaluate the linkage disequilibrium (LD), we calculated the D and r 2 value using SNPAlyze version 3.0 software (DYNACOM, Mobara, Japan).
Results
The Lys198Asn Polymorphism Did Not Affect the ET-1 and Big ET-1 Levels in the Culture Supernatant
To examine whether the Lys198Asn polymorphism in the EDN1 gene affects production of ET-1, COS1 cells were transfected with either a Lys-type plasmid or Asn-type plasmid, and the amounts of secreted ET-1 were measured by ELISA. Since ECE is expressed in many cell lines, including COS1 cells, preproET-1 should be converted to ET-1. In the culture supernatant collected from the cells transfected with either the Lys-type or Asn-type plasmid, higher levels of ET-1 were detected as compared with that in cells transfected with the vector alone ( Fig. 2A, left panel) . No difference in ET-1 level was observed between the Lys-type and Asn-type transfected cells (Fig 2A, left panel) . We also measured the big ET-1 levels. The amount of big ET-1 in the supernatant was much higher than that of ET-1, and also was not significantly different between Asn-type and Lys-type transfected cells ( Fig. 2A, right panel) . Using co-transfected pMI-SEAP plasmid, we normalized the transfection efficiency of the plasmids, but the results were same.
Regarding the other cell lines, 293 cells and HUVECs, there were no significant differences in either the ET-1 or big ET-1 levels in the culture supernatant between Asn-type and Lys-type transfected cells, as indicated in COS1 cells (Fig.  2B, C) . Normalization of the transfection efficiency by cotransfection of pMI-SEAP plasmid did not alter the results.
Relationship between EDN1 Gene Polymorphism and Plasma ET-1 Level in Hypertensives
We assessed the difference in plasma ET-1 level between genotypes in Lys198Asn (5727G>T) and 3A/4A ( 134delA) in 54 patients with essential hypertension (mean age: 61.0 12.8 years old; male/female: 30/24; mean BMI: 25.3 3.6 kg/m 2 ; mean BP: 144.5 17.3/82.2 10.5 mmHg). As shown in Fig. 3A , the plasma levels of ET-1 tended to be higher in subjects with the Asn-allele (GT TT) than in homozygotes with 198Lys (GG), but the difference was not significant ( p 0.057). In contrast, there was a significant difference in plasma ET-1 level between 3A/3A and 3A/4A (Fig. 3B ). There were no differences in age, sex, BMI, BP levels or renal function between the two genotypes of these EDN1 gene polymorphisms (data not shown).
Discussion
Several reports have described that the Lys198Asn polymorphism in preproET-1 showed a positive association with BP elevation in overweight people, and this was observed not only in Caucasians but also in Japanese (9) (10) (11) . Another study focusing on pregnant women showed that the Asnallele was associated with SBP, and homozygotes with Asn198 had a significantly increased level of plasma ET-1 compared to women with other genotypes (12) . These studies suggested that the Lys198Asn polymorphism may affect BP regulation through the production of ET-1. However, none of the studies examined the functional consequence of the Lys198Asn polymorphism on preproET-1. Because the Lys198Asn polymorphism is located in the coding region of the EDN1 gene, it is likely that the polymorphism affects the processing of preproET-1 rather than modifying the gene expression or the stability of the mRNA. Here, we have designed a strategy to test this hypothesis by expressing the Lys-type and Asn-type preproET-1 transiently in three different cell lines, COS1 cells, 293 cells and HUVECs. The results showed that neither ET-1 nor big ET-1 levels in the culture supernatant of the Asn-type transfected cells were significantly changed compared to those of the Lys-type transfected cells.
The amount of big ET-1 in the medium was much higher than that of ET-1 in all cell types (Fig. 2) . ET-1 is synthesized from big ET-1 through proteolytic cleavage by ECE. The large amount of big ET-1 in the culture supernatant indicated the inefficient cleavage of big ET-1 by endogenous ECE, because transient expression of preproET-1 using cytomegalovirus promoter would result in overproduction of big ET-1 for the endogenous enzyme.
It has been reported that ET-1[1-31], a peptide 10 amino acids longer than ET-1, is synthesized from big ET-1 by the proteolytic action of chymase and is also bioactive (19) (20) (21) . The Lys198Asn polymorphism might affect the production of ET-1 . Unfortunately, in the present study, ET-1 could not be detected in the culture supernatant by ELISA (data not shown), probably due to the very low activity of chymase in the cells that we used.
In the measurement of the plasma ET-1 level in the 54 patients with essential hypertension, we were not able to find a significant difference between the genotypes in the EDN1 Lys198Asn polymorphism, though the Asn-allele subjects tended to have a higher plasma ET-1 level than subjects with the Lys-allele. This finding seems to be concordant with the results obtained from the transfection study. Barden et al., however, reported that plasma ET-1 levels were increased in Asn homozygotes in pregnant women (12) . In addition, the positive correlation between this polymorphism and high BP has been observed only in overweight subjects (9, 10) . Thus, it is suggested that a study focusing on normotensives is necessary, because the expression and/or production of ET-1 might be modified by BP or other factors such as obesity. Furthermore, the interaction between the EDN1 Lys198Asn polymorphism and other factors, such as insulin resistance or activation of the renin-angiotensin system, may be involved in the mechanisms elevating BP in vivo.
An association between hypertension and the 3A/4A polymorphism (-134delA) located 138 bp downstream from the transcription start site in the 5 -untranslated region in the EDN1 gene has been reported (14, 15) . Popowski et al. reported that the HUVECs obtained from homozygotes with the 4A-allele type showed a significantly increased expression of ET-1 protein due to enhanced mRNA stability (16) . In the present study, significantly higher plasma ET-1 levels were observed in hypertensive subjects with the 4A-allele compared to 3A/3A homozygotes, although Popowski et al. could not find increased expression of ET-1 in the HUVECs obtained from heterozygotes. The reason why they did not observe the increased secretion of ET-1 in the ex vivo system was likely due to the difference in the background of the individuals-that is, they obtained their results using HUVECs from healthy German newborns and our results were obtained from Japanese hypertensives. LD analysis revealed that the Lys198Asn and 3A/4A polymorphisms are slightly in LD (D 0.65, r 2 0.20). In the present study, the tendency for a positive correlation between the Lys198Asn polymorphism and plasma ET-1 levels was also recognized.
In conclusion, our results indicated that the EDN1 Lys198Asn polymorphism did not directly affect ET-1 production in the expression assay using cultured transfected cells. Therefore, we propose that another variant having LD with this polymorphism, such as maybe the 3A/4A polymorphism, might be responsible for the association with BP elevation via plasma ET-1 up-regulation, or the interaction between the EDN1 Lys198Asn polymorphism and other factors such as obesity might be involved in the mechanisms elevating BP in vivo.
